Key Points in This Article:
-
Oscar Health’s (OSCR) stock surged in June 2025 due to strong Q1 earnings but crashed after Centene’s guidance withdrawal and analyst downgrades.
-
Regulatory risks, rising costs, and potential ACA enrollment declines challenge OSCR’s recovery prospects.
-
Strong cash reserves and AI-driven innovations provide growth potential, but high valuation and competition limit upside.
-
Nvidia made early investors rich, but there is a new class of ‘Next Nvidia Stocks’ that could be even better. Click here to learn more.
Is OSCR in Good Health?
Oscar Health (NYSE:OSCR) is a technology-driven health insurance company specializing in individual, family, and small group plans, primarily through Affordable Care Act (ACA) exchanges.
Its platform leverages artificial intelligence (AI) and data analytics to enhance member experiences, streamline care delivery, and optimize costs. In June 2025, OSCR’s stock surged, peaking at $22.09 on July 1, driven by
However, the stock has cratered 39% from that high and is 43% below its recent May 2024 peak of $23.79 per share. The downfall was initially triggered by Centene’s (NYSE:CNC) withdrawal of its 2025 guidance, which was due to rising medical costs and ACA market challenges. Analyst downgrades and ongoing sector pressures have since kept OSCR’s price depressed, raising questions about its recovery potential.
Can OSCR Bounce Back?
Analysts are cautious, with a consensus one-year price target of $12.42 per share. Barclays’ Street-high of $17 (set July 2 after the initial plunge) though the analyst paired it with an underweight rating due to ACA subsidy expiration risks and rising exchange acuity (e.g., there are more unhealthy enrollees in the program increasing its costs).
Wells Fargo and UBS downgraded OSCR to underweight and sell, citing potential 30% enrollment drops by 2026. OSCR relies heavily on ACA markets, which account for 90% of its premiums, making it vulnerable to regulatory changes. Its high P/E ratio of 30.8 and low EBIT margins stand in contrast to peers like Centene and Molina Healthcare (NYSE:MOH), which trade at significantly lower multiples.
These factors suggest Oscar Health has a challenging path to a $20 share price by the end of 2026.
It’s Not All Bad
Despite headwinds, OSCR boasts strengths that could fuel a rebound. Its 141% revenue growth over five years outpaces competitors, and a $3 billion cash reserve offers flexibility. AI-driven innovations, such as care routing and virtual urgent care, are designed to improve member response times and provider efficiency, potentially lowering claims costs and improving margins.
Analyst projections estimate earnings reaching $1.19 per share by the end of 2026, implying a $16 to $17 share price at a 14x multiple. If we assign a 20x multiple, we get a stock price closer to $24 per share.
However, regulatory uncertainties, such as the expiration of enhanced ACA subsidies by December 2025 (potentially reducing enrollment by 7.4 million by 2030, according to Congressional Budget Office estimates), and competition from diversified insurers like UnitedHealth temper optimism, suggesting a 14x multiple is more reasonable.
The Market Isn’t Too Hopeful
OSCR stock dropped again following additional analyst downgrades, reflecting market skepticism. While OSCR’s $1.2 billion free cash flow and the $4.5 trillion U.S. healthcare market indicate potential upside, insider selling as its stock rose in June, and reduced institutional stakes (though they still hold 90% of OSCR’s float) signal caution.
OSCR’s historical failure to reclaim its all-time high of $36.77 per share in 2021 underscores its struggle to sustain momentum amid sector volatility.
Key Takeaway
The post Is $20 a Fair Valuation for Oscar Health (OSCR) — or a Stretch Too Far? appeared first on 24/7 Wall St..
